Literature DB >> 21034964

Insights into the evolution of lymphomas induced by Epstein-Barr virus.

David Vereide1, Bill Sugden.   

Abstract

Epstein-Barr virus (EBV) encodes a wealth of oncogenic instructions, including the abilities to drive a resting normal B cell to proliferate and to override apoptotic stimuli. EBV is found in almost all types of lymphomas at varying frequencies. However, the particular viral genes expressed differ considerably among tumors. We have examined the role of EBV in several lymphomas by conditionally evicting the extrachromosomal viral genome from tumor cells in vitro and have found a graded dependence on the virus. Tumor cells that express all the known latent viral genes have been found to depend on the virus to drive proliferation and to block apoptosis at least in part by repressing the proapoptotic protein Bim. Other tumor cells, which express fewer viral genes, also depend on the virus to block apoptosis, but rely on the virus to promote but not to drive proliferation. Lastly, tumor cells with the fewest viral genes expressed have been found to require EBV to prevent the inefficient induction of a Bim-independent apoptosis. We present a model for the evolution of EBV-induced lymphomas in which tumors are initially "addicted" to the virus for almost all oncogenic functions. These tumors are targets for the immune system because they express multiple immunogenic viral proteins. Therefore, EBV-induced tumors are under selective pressure to acquire cellular mutations that can replace viral functions. We posit that the heterogeneity in viral gene expression among different EBV-associated lymphomas reflects a dynamic process by which tumors evolve to be less dependent on the virus.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21034964     DOI: 10.1016/B978-0-12-380888-2.00001-7

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  15 in total

Review 1.  Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications.

Authors:  Jiezhong Chen
Journal:  World J Virol       Date:  2012-12-12

2.  Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential.

Authors:  Shi-Dong Ma; Ming-Han Tsai; James C Romero-Masters; Erik A Ranheim; Shane M Huebner; Jillian A Bristol; Henri-Jacques Delecluse; Shannon C Kenney
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

3.  LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.

Authors:  Shi-Dong Ma; Xuequn Xu; Julie Plowshay; Erik A Ranheim; William J Burlingham; Jeffrey L Jensen; Fotis Asimakopoulos; Weihua Tang; Margaret L Gulley; Ethel Cesarman; Jenny E Gumperz; Shannon C Kenney
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808

4.  Epstein-Barr virus maintains lymphomas via its miRNAs.

Authors:  D T Vereide; E Seto; Y-F Chiu; M Hayes; T Tagawa; A Grundhoff; W Hammerschmidt; B Sugden
Journal:  Oncogene       Date:  2013-03-18       Impact factor: 9.867

Review 5.  Impact of EBV essential nuclear protein EBNA-3C on B-cell proliferation and apoptosis.

Authors:  Abhik Saha; Erle S Robertson
Journal:  Future Microbiol       Date:  2013-03       Impact factor: 3.165

6.  Adoptively transferred Vγ9Vδ2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model.

Authors:  Nicholas A Zumwalde; Akshat Sharma; Xuequn Xu; Shidong Ma; Christine L Schneider; James C Romero-Masters; Amy W Hudson; Annette Gendron-Fitzpatrick; Shannon C Kenney; Jenny E Gumperz
Journal:  JCI Insight       Date:  2017-07-06

7.  Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with Epstein-Barr virus.

Authors:  Kui Chen; Sharif Ahmed; Oyedele Adeyi; John E Dick; Anand Ghanekar
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

8.  TRAF1 Coordinates Polyubiquitin Signaling to Enhance Epstein-Barr Virus LMP1-Mediated Growth and Survival Pathway Activation.

Authors:  Hannah Greenfeld; Kaoru Takasaki; Michael J Walsh; Ina Ersing; Katharina Bernhardt; Yijie Ma; Bishi Fu; Camille W Ashbaugh; Jackson Cabo; Sarah B Mollo; Hufeng Zhou; Shitao Li; Benjamin E Gewurz
Journal:  PLoS Pathog       Date:  2015-05-21       Impact factor: 6.823

Review 9.  Immune checkpoint inhibitors in lymphoma: challenges and opportunities.

Authors:  Haris Hatic; Devi Sampat; Gaurav Goyal
Journal:  Ann Transl Med       Date:  2021-06

10.  PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model.

Authors:  Shi-Dong Ma; Xuequn Xu; Richard Jones; Henri-Jacques Delecluse; Nicholas A Zumwalde; Akshat Sharma; Jenny E Gumperz; Shannon C Kenney
Journal:  PLoS Pathog       Date:  2016-05-17       Impact factor: 7.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.